France’s Medical Cannabis Market Is Still Waiting for a Decree After the Patient Bridge Ran Out

Only 1,683 patients were still in the system as France’s bridge period expired

France’s medical-cannabis market is still not properly open. The clearest number is also the smallest one. A Senate written question published on January 22 said that only 1,683 patients were still benefiting from the program when the question was filed, even though more than 3,200 patients had entered since the experiment began.

That would already be a sign of contraction. It matters more because France had already stopped new admissions long before that point. A French government patient-information page states that no new patient has been allowed into the scheme since March 27, 2024. The experiment itself ended on December 31, 2024. After that came a transition period, running from January 1, 2025 to March 31, 2026, designed to keep treatment going for patients who were already inside.

That transition has now ended. Yet the permanent framework still has not produced a functioning commercial market. A National Assembly question dated May 5 says the sector is still waiting for the decree expected before June 2026. In practical terms, France has moved past a missed administrative target and into a market-timing problem. Patients already in treatment have lived through a long wind-down. Companies that hoped to supply the next phase are still waiting for the state to turn its own rulebook into a live system.

The significance is wider than patient access. The missing decree affects every part of the proposed chain: cultivators that want to grow in France, importers that expected to bring finished products in, manufacturers preparing controlled production, pharmacies that would dispense the medicines, and investors trying to decide whether the French market is merely delayed or still structurally uncertain. The policy outline exists. The market does not.

Brussels saw the draft texts in March 2025, but Paris still has not switched them on

France is not blocked because it failed to sketch out a framework. The unusual feature of this story is that the state has already done much of the technical drafting.

On March 19, 2025, France notified three core texts to the European Union through the bloc’s technical rule notification system. That system is a pause-and-comment process used when a member state plans technical market rules that could affect trade. It does not create the French market by itself. It does, however, show that France had a detailed model ready to present to Brussels.

The first text was the central decree on medical cannabis. According to the notification record, it would create a five-year authorization pathway run by the French medicines agency, ANSM, for cannabis-based medicines that are not otherwise covered by standard drug approval routes. It also set a 210-day review period, post-authorization safety obligations, and rules for manufacturing and import. In plain terms, this was the gatekeeping text. It said who could apply, how long the regulator would take to review a file, and what safety and supply rules would apply once a product was on the market.

The second text set product specifications and therapeutic indications, meaning the types of products France would accept and the medical situations in which they could be used. This matters because it shows how narrow the French model is likely to be. The notified text excludes raw dried cannabis flower. It does allow certain fast-acting cartridge formats. That is not a minor packaging detail. It tells producers and prescribers that France is aiming at a pharmaceutical format market, not a broad flower market that resembles consumer cannabis systems elsewhere.

The third text covered the physical chain itself: possession, cultivation, import, export, transport, and storage of the cannabis plant for medical purposes on French territory. It set conditions for domestic cultivation, including a required contract between the grower and an authorized pharmaceutical establishment. That means a cultivator would not simply plant and sell. It would need to be tied into a licensed medical supply structure. The draft also included site-security rules and made room for production for export.

All three notifications had the same standstill end date of June 20, 2025. That date matters because it marks the point at which the EU waiting period had run its course. After that, the remaining blockage was domestic. France still needed to adopt and activate its own texts.

That is where the process has remained stuck. The May 2026 National Assembly question says the decree is still awaited before review by the Conseil d’État, the country’s highest administrative court for this type of draft rule. That is an important procedural detail because it means the delay is not about whether France can imagine the market. It is about whether the French state can complete its own internal sequence and publish the legal acts that allow the market to function.

The result is a specific kind of limbo. The experiment is over. The bridge period is over. The permanent architecture exists on paper. But the switch from controlled pilot to ordinary, if tightly regulated, patient access has not happened. For a general reader, that distinction can sound technical. For operators, it is the difference between planning around a statute and actually filing, producing, importing, dispensing, and billing.

Growers, importers, pharmacies, and investors are each waiting on a different part of the same delay

The backlog hits each group differently, but the common effect is the same: money and operational planning are being frozen by a market that has legal contours but no start signal.

For growers, the draft cultivation rules show that France is not offering an open agricultural opportunity. The model is much tighter. A grower would need a formal relationship with an authorized pharmaceutical establishment, plus security and handling measures that look more like controlled medicine production than ordinary farming. That narrows the field immediately. It favors companies that can finance compliance, build secure sites, and attach themselves to pharmaceutical operators. It is hard to build that kind of project against an uncertain timetable. Land, facilities, staff, and security contracts all cost money before a gram is sold.

For importers and manufacturers, the authorization pathway is clear enough to model but not clear enough to monetize. A company can read the draft and see the likely requirements. It can prepare product files, manufacturing controls, and safety monitoring plans. What it cannot do is start the actual regulated clock until the French state finalizes the system. Even then, the draft 210-day review period means that market entry would still take time after adoption. Every month of delay in the decree pushes first commercial sales farther out than headlines about an imminent launch might suggest.

For pharmacies, the issue is operational credibility. Dispensing medical cannabis in a pharmacy system requires stock controls, prescriber habits, patient counseling, and reimbursement clarity where relevant. Those routines do not appear by decree alone. They develop through use. France has spent two years restricting entry rather than expanding it. No new patient has been able to join since March 2024, and the remaining patient base has fallen sharply. That makes the eventual rollout harder, not easier, because the network of daily practice has been shrinking while the legal framework has been sitting unfinished.

For doctors and existing patients, the long pause changes the program’s shape. The original experiment was supposed to generate real-world experience around prescribing and dispensing. A closed intake model does the opposite. It preserves continuity for a diminishing group while preventing any broader normalization. That may be administratively cautious, but it reduces the practical evidence base that comes from routine use across a stable clinical population.

For investors, the French case now looks less like a classic question of whether the state wants medical cannabis and more like a question of whether administrative execution can be trusted. The three notified texts show that France already made several key policy choices. It chose a medical-only path. It chose a product and indication list. It chose a tightly supervised domestic cultivation model. It chose a regulator-led authorization route. The current problem is not conceptual ambiguity. It is slippage between drafting and launch.

That distinction matters because delay changes the type of risk. A company can price a strict framework into a business plan. It is much harder to price repeated uncertainty around when that framework will actually exist in enforceable form. If capital cannot identify the start date, it becomes difficult to commit to facilities, supply contracts, recruitment, or local partnerships. Smaller domestic aspirants are usually hit first. Larger international groups can wait longer, redeploy capital, or treat France as an option rather than an operating necessity.

The product rules add another commercial consequence. By excluding raw dried flower and steering the market toward more standardized formats, France is shaping not only safety oversight but also the type of company that can compete. Producers built around flower-heavy supply may find the French market less suitable than those with inhalation or other pharmaceutical-format capabilities. That is not inherently a flaw. It is a policy choice. But it increases the cost of waiting, because firms must decide whether to build for a narrow French specification without knowing when the regime will begin.

The cultivation text also hints at a longer industrial ambition. It explicitly makes room for production for export. That suggests France does not see medical cannabis only as a tiny domestic access issue. At least on paper, it is considering a supply chain that could serve foreign markets too. But export ambition depends on something basic at home: an adopted framework, active licenses, and a credible domestic compliance system. Without those, industrial talk remains just that.

France has already chosen caution. The delay is now damaging credibility

A cautious medical-cannabis framework is a defensible policy position. France can legitimately decide that products should move through the medicines system, that indications should be narrow, that flower should stay out, and that cultivation should sit inside a heavily supervised pharmaceutical chain. Those choices may frustrate some operators, but they are coherent.

What is becoming harder to defend is the gap between completed drafting and incomplete execution. The evidence now shows that France notified its three key texts to Brussels more than a year ago, cleared the EU standstill period last June, let the transition for existing patients expire at the end of March, and still entered May with the sector publicly asking where the decree is. That is no longer ordinary caution. It is an administrative delay with visible commercial and clinical consequences.

The cost is not only measured in postponed revenue. It is also measured in lost institutional momentum. Every month without a live framework makes the original experiment feel less like a bridge to a stable system and more like a pilot that was allowed to shrink while the state debated how to formalize it. The patient base contracts. Prescribing routines fade. Pharmacy readiness stalls. Domestic cultivation projects remain theoretical. Capital becomes selective or leaves.

This also changes the balance of who can survive to launch. A long and uncertain pre-market period generally favors the best financed actors, especially those that can absorb delays across several countries or product lines. It is far less forgiving to smaller French entrants that hoped early preparation would be rewarded once the legal window opened. In that sense, delay is not neutral. It quietly shapes the future market before the first ordinary authorization is even issued.

If the decree arrives before June 2026, France will still not have an instant market. Companies would still face authorization reviews, supply preparation, and operational setup. The 210-day review window in the draft alone points to further lag between publication and product availability. If the decree slips again, the message becomes starker. France will have shown that it can define a medical-cannabis system in detail, present it to Europe, and still fail to activate it after its own patient bridge has already run out.

That is the real state of the market now. The question is no longer whether France has a model. It does. The question is whether the state can convert that model into a functioning medical channel before the remaining trust, patient continuity, and industrial interest thin out even further.